Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy
Travis, Lois B.*; Ng, Andrea K.†; Allan, James M.‡; Pui, Ching-Hon§; Kennedy, Ann R.**; Xu, X. George††; Purdy, James A.‡‡; Applegate, Kimberly§§; Yahalom, Joachim***; Constine, Louis S.*; Gilbert, Ethel S.†††; Boice, John D. Jr.‡‡‡
*Rubin Center for Cancer Survivorship and Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY; †Department of Radiation Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; and the Dana-Farber Cancer Institute, Boston, MA; ‡Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK; §Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN; and the University of Tennessee Health Science Center, Memphis, TN; **Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA; ††Nuclear Engineering and Engineering Physics Program, Rensselaer Polytechnic Institute, Troy, NY; ‡‡Department of Radiation Oncology, University of California at Davis, Davis, CA; §§Department of Radiology, Emory University, Atlanta, GA; ***Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY; †††Division ofCancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; ‡‡‡National Council on Radiation Protection and Measurements, Bethesda, MD, and the Department of Medicine, Vanderbilt University, Nashville, TN.
The authors declare no conflicts of interest.
For correspondence contact: Lois B. Travis, Rubin Center for Cancer Survivorship and Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, 265 Crittenden Blvd, CU 420318, Rochester, NY 14642, or email at Lois_Travis@URMC.Rochester.edu.
Article reprinted with permission from Journal of the National Cancer Institute. Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, Purdy JA, Applegate K, Yahalom J, Constine LS, Gilbert ES, Boice JD. Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. JNCI J Natl Cancer Inst (2012) 104 (5): 357-370. doi: 10.1093/jnci/djr533.
Supplemental Digital Content is available in the HTML and PDF versions of this article on the journal’s Web site (www.health-physics.com).
(Manuscript accepted 13 July 2013)
Abstract: Second malignant neoplasms (SMNs) and cardiovascular disease (CVD) are among the most serious and life-threatening late adverse effects experienced by the growing number of cancer survivors worldwide and are due in part to radiotherapy. The National Council on Radiation Protection and Measurements (NCRP) convened an expert scientific committee to critically and comprehensively review associations between radiotherapy and SMNs and CVD, taking into account radiobiology; genomics; treatment (i.e., radiotherapy with or without chemotherapy and other therapies); type of radiation; and quantitative considerations (i.e., dose-response relationships). Major conclusions of the NCRP include: (1) the relevance of older technologies for current risk assessment when organ-specific absorbed dose and the appropriate relative biological effectiveness are taken into account and (2) the identification of critical research needs with regard to newer radiation modalities, dose-response relationships, and genetic susceptibility. Recommendation for research priorities and infrastructural requirements include (1) long-term large-scale follow-up of extant cancer survivors and prospectively treated patients to characterize risks of SMNs and CVD in terms of radiation dose and type; (2) biological sample collection to integrate epidemiological studies with molecular and genetic evaluations; (3) investigation of interactions between radiotherapy and other potential confounding factors, such as age, sex, race, tobacco and alcohol use, dietary intake, energy balance, and other cofactors, as well as genetic susceptibility; (4) focusing on adolescent and young adult cancer survivors, given the sparse research in this population; and (5) construction of comprehensive risk prediction models for SMNs and CVD to permit the development of follow-up guidelines and prevention and intervention strategies.
ADVANCES IN cancer therapy, early detection, and supportive care have contributed to steady gains in the 5 y relative survival rate for all cancers combined, which reached 66.0% for patients diagnosed during 1999–2006 (Altekruse et al. 2010). Commensurately, the number of cancer survivors in the United States has tripled since 1971 and is growing by 2% each year. As of 2007, there were ~12 million men and women in the United States (~3.5% of the U.S. population) with a history of cancer (Altekruse et al. 2010). For many patients, these gains in survival have come at the price of serious treatment-associated late adverse effects.
Radiation remains a cornerstone of successful cancer treatment, with 50% of all patients estimated to receive radiotherapy (Ringborg et al. 2003). Second malignant neoplasms (SMNs) and cardiovascular disease (CVD) are two of the most frequent and important life-threatening adverse events associated with radiotherapy. Multiple primary cancers now account for approximately one in six of all incident cancers reported to the US Surveillance, Epidemiology, and End Results Program cancer registry (Altekruse et al. 2010). For patients with Hodgkin lymphoma (Ng et al. 2002a), testicular cancer (van den Belt-Dusebout et al. 2007; Travis et al. 2010), and certain childhood cancers (Friedman et al. 2010), SMNs have emerged as an important cause of death (Travis et al. 2011). Radiotherapy-associated CVD refers to a wide spectrum of disorders and is an important cause of morbidity and mortality, most notably after thoracic radiotherapy for Hodgkin lymphoma and tangential radiotherapy for breast cancer (Yahalom and Portlock 2008; Mulrooney et al. 2009).
With the increased awareness of the adverse consequences of cancer therapy, it has become critically important to identify measures to mitigate and ameliorate these late adverse effects and to provide cancer survivors with counseling, surveillance, and supportive care. In addition, it is essential to review and balance the risks and benefits of new treatment options as they become available. Providing a research infrastructure for transdisciplinary studies of cancer survivors is also important (NCI 2010). The Childhood Cancer Survivors Study (CCSS) is a critical resource for outcome and intervention research in survivors of pediatric and adolescent cancer (Robison et al. 2009); however, a comparable research base is lacking for survivors of young adult-onset (Travis et al. 2006; Bhatia and Robison 2008) and other cancers. The expanding use of radiotherapy and development of new radiation modalities to treat cancer, coupled with improvements in long-term patient survival, underscores the importance of continuing to provide long-term risk estimates as well as additional research into the molecular underpinnings of treatment-related SMNs and CVD. Moreover, optimal screening and interventional efforts for these late adverse events must be identified (Travis et al. 2010).
To review and address the expanding burden of late adverse effects after treatment with radiation, the National Council on Radiation Protection and Measurements (NCRP) convened a scientific committee of experts in radiation biology, radiation oncology, radiation physics, molecular genetics, medical oncology, pediatric oncology, cardiology, biostatistics, and epidemiology to comprehensively review radiotherapy-associated SMNs and CVD and recommend future research. This article provides a synthesis of the 425-page NCRP report titled Second Primary Cancers and Cardiovascular Disease After Radiotherapy (NCRP 2011).
The traditional paradigm for the genesis of radiation-induced adverse effects, such as cell killing and carcinogenesis, is that biological responses result from the deposition of energy in or near cellular DNA (Little 2000). Radiation then interacts with DNA, either directly via ionization or indirectly via water-derived free radicals, resulting in genetic and/or epigenetic changes that are passed on to cellular progeny and that can contribute to malignant transformation. However, based on both in vitro and in vivo studies, there is increasing realization that low doses of radiation (e.g., <0.5 Gy) may also contribute to radiation-induced adverse effects such as carcinogenesis and CVD (UNSCEAR 2009). Differences in cellular responses to “low” vs. “high” doses of radiation have also been reported for a number of different biological endpoints, including DNA damage signaling, cell cycle checkpoint activation, DNA repair, gene and protein expression, apoptosis, and cell transformation (Averbeck 2009). However, evidence is emerging that radiation-induced carcinogenesis may be a modifiable process (Kennedy 2009). For example, some agents appear to be capable of either reducing or increasing the incidence of radiation-induced cancer in animal models (Fry and Ley 1984; Burns et al. 2007; Kennedy et al. 2008). Given this prospect, more research is needed to identify clinical interventions to reduce late adverse effects of radiotherapy.
GENETIC FOUNDATIONS OF LATE EFFECTS OF RADIOTHERAPY
Data from animal models and human studies demonstrate that the genotype of the host influences the risk of radiation-associated late effects. For example, patients who inherit rare pathogenic mutations in genes associated with human cancer susceptibility syndromes are predisposed to radiogenic cancers, including TP53 mutations in Li-Fraumeni syndrome (Nutting et al. 2000; Limacher et al. 2001; Talwalkar et al. 2010), NF1 mutations in neurofibromatosis (Little et al. 1998; Sharif et al. 2006), PTCH1 mutations in Gorlin syndrome (Wallin et al. 2007), WT1 mutations in Wilms tumor (Bassal et al. 2006; Henderson et al. 2007; Breslow et al. 2010), and RB1 mutations in retinoblastoma (Wong et al. 1997; Kleinerman et al. 2005). The increased susceptibility of mice heterozygous for the murine homologs of PTCH1 (Pazzaglia et al. 2004, 2006), TP53 (Backlund et al. 2001), and NF1 (Chao et al. 2005) to radiogenic cancers suggests the importance of these loci in human radiogenic cancers. The well-characterized roles of BRCA1, BRCA2, and ATM in mediating cellular response to ionizing radiation have prompted speculation that germline mutations associated with hereditary cancer may also predispose the mutation carriers to radiogenic cancer, particularly in the contexts of contralateral breast cancer (Bernstein et al. 2010; Graeser et al. 2009) and radiotherapy for Hodgkin lymphoma (Nichols et al. 1999; Offit et al. 2002). However, whether pathogenic mutations in these loci confer increased susceptibility to radiogenic cancer remains controversial. Several studies found no association (Nichols et al. 1999; Offit et al. 2002; Narod et al. 2006), whereas others provided limited evidence suggesting that specific ATM (Bernstein et al. 2010) and BRCA1 (Graeser et al. 2009) alleles may be associated with increased risk of breast cancer, particularly in BRCA1 mutation carriers exposed to radiotherapy before age 40 y (Andrieu et al. 2006; Berrington de Gonzalez et al. 2009; Graeser et al. 2009).
Many human cancer susceptibility genes that encode proteins that mediate cellular responses to ionizing radiation have a high frequency of genetic variants. For example, polymorphisms in TP53 and ATM, with corresponding amino acid changes in the respective proteins, can affect the cellular response to ionizing radiation (Angèle et al. 2003; Gutiérrez-Enríquez et al. 2004; Li et al. 2005; Zhu et al. 2010), making them candidate risk modifiers for radiogenic cancer and other late adverse effects of radiotherapy in a polygenic disease. Targeted gene- and/or pathway-based studies investigating adverse events after low- (Lönn et al. 2007; Sigurdson et al. 2007, 2009a; Bhatti et al. 2008a, 2008b, 2010; Rajaraman et al. 2008; Schonfeld et al. 2010) and high-dose (Chang-Claude et al. 2005, 2009; De Ruyck et al. 2006; Tan et al. 2006; Azria et al. 2008; Burri et al. 2008; Kuptsova et al. 2008; Pugh et al. 2009; Sigurdson et al. 2009b; Werbrouck et al. 2009; Yoshida et al. 2009; Zhang et al. 2010) radiation exposure have identified numerous other variants, loci, and pathways that warrant further investigation; others are readily testable based on known gene-exposure interactions identified by in vitro and ex vivo studies (Zheng et al. 2010). Genome-wide association studies (Knight et al. 2009; Ingle et al. 2010; Best et al. 2011) might identify new gene-exposure interactions; however, this approach will require large well-controlled studies with sufficient statistical power to account for various phenotypic and exposure-related risk factors. Indeed, a genome-wide approach led to the discovery of an allelic variant in PRDM1 (also known as BLIMP1), a gene that predisposes Hodgkin lymphoma survivors to radiogenic cancer (Best et al. 2011). As parallel approaches, whole-genome (Cirulli and Goldstein 2010) or exon-based sequencing technologies could prove equally informative. The ongoing development of radiogenomics consortia (West et al. 2010) with annotated biospecimens is anticipated to provide additional data with regard to genetic variants that may increase the risk for radiogenic cancer.
The low frequencies of overtly pathogenic alleles, such as TP53 and ATM, suggest that they make a relatively small contribution at the population level. In addition, the heterogeneous patient responses to the acute and chronic effects of radiotherapy imply that these toxicities have complex genetic etiologies, rather than representing a monogenic trait. Furthermore, the fact that a single susceptibility locus with high-penetrance allelic variants for radiogenic cancer has not yet, to our knowledge, been identified further underscores the hypothesis that susceptibility to radiogenic cancer constitutes a polygenic trait, where cumulative risk is determined by co-inheritance of multiple low- and/or intermediate-penetrance “risk” alleles at several different loci, including, for example, PRDM1 (Best et al. 2011). Understanding how multiple variants interact with each other and with radiation and phenotypic risk modifiers should be considered when developing risk prediction models to inform intervention strategies. Indeed, the inclusion of genetic data has substantially improved the accuracy of risk prediction models for SMNs or recurrence after head and neck cancer (Wu et al. 2009). Risk models that integrate genotypic, phenotypic, and treatment data and other variables should also be developed for Hodgkin lymphoma (Longo 2005; Travis et al. 2005a) and other malignancies (Travis et al. 2010) where SMNs, CVD, and other late effects are important causes of morbidity and mortality.
An understanding of genetic and molecular factors that predispose individuals to the development of radiotherapy-induced cancers will also provide a foundation for the study of other late effects of radiation that have, in part, a known genetic basis, including CVD (Hindorff et al. 2009; NHGRI 2010). Although some genetic risk factors will undoubtedly be effect specific, the observation that some human diseases have overlapping transcriptional signatures in pathways such as lipid metabolism and carcinogenesis suggests that some pathways might apply to seemingly unrelated radiation-induced late effects, including cancer and CVD (Hirsch et al. 2010). Other pathways directly responsible for mediating cellular response to ionizing radiation are also likely to involve nonspecific risk factors. For example, radiation-induced reactive oxygen species can initiate an inflammatory response that leads to genomic instability and fibrosis, which have been implicated in the etiologies of cancer and CVD, respectively. In addition, Wethal et al. (2010) showed that long-term survivors of testicular cancer with elevated serum levels of C-reactive protein, which is produced in response to inflammatory stimuli, had a two- to threefold increased risk of developing either SMN [hazard ratio (HR) = 2.21; P < 0.05] or CVD (HR = 2.79; P < 0.05).
RADIOTHERAPY MODALITIES, TECHNOLOGIES, AND DOSIMETRY
Technical innovations have changed the practice of radiotherapy (Purdy 2007). Modern anatomical imaging technologies provide three-dimensional anatomical models of the patient that are often complemented with functional imaging studies such as positron emission tomography or magnetic resonance spectroscopy. Advanced imaging results in a more accurate determination of the tumor volumes and spatial relationships with the surrounding tissue and organs. Three-dimensional treatment planning systems, which take full advantage of these imaging advances, have facilitated the implementation of three-dimensional conformal radiation therapy as a standard of practice (Purdy 2007).
The development of medical linear accelerators equipped with computer-controlled multileaf collimator systems along with advanced computer-based treatment planning systems allow precise shaping of radiation dose distributions for each patient. Intensity-modulated radiation therapy (IMRT) can achieve even greater dose conformity through a computer-aided optimization process that creates a fluence of photons per radiation beam that is customized to the patient (IMRTCWG 2001). The use of conformal radiation therapy has further evolved from IMRT to image-guided IMRT, also called image-guided radiation therapy. For very small tumor volumes adjacent to sensitive critical structures, cobalt-60 and linear accelerator-based stereotactic radiosurgery have been increasingly used in recent years, and new image-guided stereotactic body radiation therapy systems have been developed (Leksell 1951, 1968; Lutz et al. 1988; Brown et al. 2005).
These advances have renewed interest in the use of protons for external beam radiotherapy (Delaney and Kooy 2008). This technology allows conformal therapy to take advantage of the improved depth dose characteristics of the proton beam, which peak at the end of the range of the charged particle (Delaney and Kooy 2008). In proton therapy, there are two techniques for beam production: passive scattering and beam scanning (Delaney and Kooy 2008), with the latter method resulting in a lower amount of secondary neutrons.
The use of real-time imaging techniques to ensure the accuracy of new treatment modalities is increasing (Bortfeld et al. 2005). Although the radiation dose from a single imaging technique is small compared with a therapeutic dose, repeated and daily image-guidance procedures can lead to cumulative exposures to normal tissues and possibly a slight increase in the risk of SMN (Hall 2006). The transition from two-dimensional radiation therapy to three-dimensional conformal radiation therapy and/or IMRT has also resulted in changes in dose distribution compared with techniques used in prior SMN studies (Hodgson et al. 2007).
Advances in radiotherapy have also resulted in increased doses to normal tissue but an overall reduction in the volume of normal structures receiving high doses. However, especially with IMRT, a considerably larger volume of normal tissue within the irradiated field receives low doses. Because these doses outside the target field are much smaller than the tumor doses, they are generally not recorded in radiotherapy documentation nor are additional doses due to image-guided radiation therapy reported in medical records. This unwanted radiation leakage and scatter dose can be decreased through several designs, as reviewed elsewhere (Purdy 2008). It will be important for clinical trial quality assurance centers that monitor radiotherapy protocols to capture radiation doses to multiple organs outside radiation fields for those patients enrolled in advanced technology clinical trials to enable eventual correlation with late effects (Purdy 2008).
SMNS FOLLOWING RADIOTHERAPY FOR ADULT-ONSET CANCER
A sizable amount of SMN data has accrued for several adult-onset cancers in which radiotherapy has played pivotal roles, including Hodgkin lymphoma, non-Hodgkin lymphoma, and cancers of cervix, testis, breast, and prostate (NCRP 2011). The methods for estimating risk of SMNs from epidemiological data are described in Supplemental Digital Content 1 (http://links.lww.com/HP/A17).
Hodgkin lymphoma survivors have elevated relative risks (RRs) for most SMNs (except bladder and prostate cancers), particularly breast and lung (Hodgson et al. 2007). Radiotherapy at a young age, especially before the age of 35 y, is associated with increased breast cancer risk (Travis et al. 2003; van Leeuwen et al. 2003; Ng et al. 2002b; De Bruin et al. 2009a), whereas treatment-related premature menopause is associated with decreased risk (Travis et al. 2003; van Leeuwen et al. 2003; Basu et al. 2008; De Bruin et al. 2009a). Both radiotherapy and alkylating chemotherapy have been associated with increased risks of lung cancer (Swerdlow et al. 2001; Travis et al. 2002). The risk of SMNs for pediatric Hodgkin lymphoma survivors appears to persist following low therapeutic doses of radiation and chemotherapy (O’Brien et al. 2010). Several case-control studies, some with detailed organ-specific dose reconstructions (Travis et al. 2002, 2003; van Leeuwen et al. 2003; Stovall et al. 2008; van den Belt-Dusebout et al. 2009), have reported statistically significant trends of increasing risks of breast (Travis et al. 2003; van Leeuwen et al. 2003; Stovall et al. 2008; Mauch et al. 2005), lung (van Leeuwen et al. 1995; Travis et al. 2002), and stomach (van den Belt-Dusebout et al. 2009) cancers with increasing radiation dose among several populations of survivors of adult-onset cancer.
Survivors of non-Hodgkin lymphoma are at increased risk for SMNs (Travis et al. 1991, 1992, 1993a, 1993b, 1994, 1995, 1996; Dores et al. 2006; Mudie et al. 2006; Tward et al. 2006; Landgren et al. 2007; Sacchi et al. 2008), and some of the increased risks are associated with radiotherapy. Radiotherapy for non-Hodgkin lymphoma has been linked to increased risks of acute leukemia (Greene et al. 1983; Travis et al. 1994), bladder cancer (Travis et al. 1995; Dores et al. 2006; Mudie et al. 2006), kidney cancer (Travis et al. 1995), and mesothelioma (Tward et al. 2006; Hodgson et al. 2007; Teta et al. 2007). The use of total body irradiation as part of transplantation approaches is associated with increased risks of acute leukemia and myelodysplastic syndrome (Pedersen-Bjergaard et al. 2000; Hosing et al. 2002; Metayer et al. 2003; Brown et al. 2005) and solid tumors (Brown et al. 2005; Friedman et al. 2008; Rizzo et al. 2009), including breast cancer (Friedman et al. 2008).
Among testicular cancer survivors, past treatment with large-field radiotherapy is statistically significantly associated with the risk of leukemia; past treatment with infradiaphragmatic radiation is associated with a threefold increased non-statistically significant risk of leukemia (Travis et al. 2000). Statistically significant increased risks of cancers of the lung, thyroid, esophagus, stomach, pancreas, colon, rectum, kidney, bladder, and connective tissue have also been observed among long-term survivors of testicular cancer (Travis et al. 2005b). These SMNs typically represent nontarget sites that were included in radiation fields (Travis et al. 2005b). Concerns about radiation-related SMNs have prompted the adoption of observation-alone strategies following stage I seminoma (Chung et al. 2010).
Cancers associated with breast cancer radiotherapy include those of the contralateral breast (Boice et al. 1992; Hemminki et al. 2007; Kirova et al. 2007; Hooning et al. 2008; Stovall et al. 2008), lung (Kirova et al. 2007; Deutsch et al. 2003; Zablotska and Neugut 2003; Kaufman et al. 2008), and esophagus (Zablotska et al. 2005), as well as sarcoma (Kirova et al. 2005). The risk of contralateral breast cancer after radiotherapy for breast cancer appears to be limited to women who are younger than age 40–45 y at receipt of radiotherapy (Boice et al. 1992; Hooning et al. 2008; Stovall et al. 2008) and is dose related (Stovall et al. 2008). Risks for cancers of the lung and esophagus are higher after postmastectomy radiotherapy than after post lumpectomy radiotherapy (Zablotska and Neugut 2003; Zablotska et al. 2005; Kaufman et al. 2008), likely reflecting the differing volumes of normal tissue in the treatment fields. Although the risk of sarcoma after breast cancer radiotherapy is increased compared with the risk of sarcoma in the general population, radiation-induced sarcoma remains a rare event (absolute risk <0.5% at 15 y after radiotherapy) (Kirova et al. 2005).
Kleinerman et al. (1982) reported that radiotherapy for cervical cancer was associated with statistically significantly increased risks of cancers of bladder, kidneys, rectum, corpus uteri, and ovaries; these findings were confirmed in subsequent surveys (Boice et al. 1987, 1988; Kleinerman et al. 1995). In the most recent update (Chaturvedi et al. 2007), the risks for several solid pelvic tumors remained statistically significantly elevated for more than 40 y after radiotherapy.
Some (Brenner et al. 2000; Pickles and Phillips 2002; Moon et al. 2006; Abdel-Wahab et al. 2009), but not all (Movsas et al. 1998; Chrouser et al. 2005; Kendal et al. 2006), studies have reported increased risks of colorectal cancer, bladder cancer, soft tissue sarcoma, and lung cancer among men treated with radiation for prostate cancer. The absolute risk of developing any SMN appeared modest (1 in 290 patients) (Brenner et al. 2000), and some excess SMNs were detected incidentally during colonoscopies or cystoscopies.
SMNS FOLLOWING RADIOTHERAPY FOR CHILDHOOD CANCER
The risk of SMNs among childhood cancer survivors is associated with radiotherapy, chemotherapy, and genetic predisposition. In a recent CCSS update (Friedman et al. 2010), the cumulative incidence of all subsequent neoplasms at 30 y after diagnosis was 20.5% [95% confidence interval (CI) = 19.1–21.8%] among 5 y survivors of childhood cancer treated from 1970 through 1986 and was higher for patients who received radiation therapy than for those who did not (~25 vs. 10%); radiation therapy exposure was associated with a statistically significantly increased risk of a subsequent neoplasm (RR = 2.7, 95% CI = 2.2–3.3). Overall, cumulative incidence of SMNs at 30 y of follow-up was 7.9%, and, again, was higher among patients who received radiotherapy than among those who did not receive radiotherapy (~10 vs. 5%). Radiotherapy was associated with increased risks of secondary central nervous system tumors, bone and soft tissue sarcomas, thyroid cancer, and non-melanoma skin cancer. A more recent CCSS report showed that, overall, patients who developed a second neoplasm had a cumulative incidence of developing yet another primary cancer by 20 y after the SMN of 46.9%; the cumulative incidence of an additional primary cancer after an SMN was 41.3% among patients who received radiotherapy for the first cancer compared with 25.7% for those not treated with radiation; however, treatment for the SMN was not considered in these estimates (Armstrong et al. 2011). A study of 5 y survivors of childhood solid tumors in Great Britain and France showed an association between integral radiation dose and risk of death from SMNs, with secondary carcinoma as the leading cause of death, followed by sarcoma and then hematological malignancies (Tukenova et al. 2011). Survivors of hereditary retinoblastoma have the highest risk of SMNs, with a cumulative incidence at 50 y after diagnosis of 36% (95% CI = 31–41%) compared with 5.7% (95% CI = 2.4–11%) for survivors of nonhereditary retinoblastoma (Kleinerman et al. 2005).
Among survivors of nonfamilial or hereditary malignancies, survivors of Hodgkin lymphoma appear to have the highest overall risk for SMNs. In a recent CCSS report of 2,742 Hodgkin lymphoma survivors, of whom 94% received radiation (Castellino et al. 2011), the 30 y cumulative incidence of any SMN was 10.9% (95% CI = 8.3–13.4%) in males and 26.1% (95% CI = 22.4–29.8%) in females; the difference in cumulative incidence was due to invasive breast cancer (cumulative incidence = 18.3%; 95% CI = 16.0–20.6%). The highest absolute excess risks (excess cancers per 10,000 person-y of follow-up) were observed for the following solid cancers: bone = 22.3 (95% CI = 10.0–49.6), thyroid = 17.6 (95% CI = 13.0–24.0), and breast = 17.0 (95% CI = 14.0–21.7).
The median time from Hodgkin lymphoma diagnosis to diagnosis of invasive breast cancer was 21.0 y (range = 6.7–33.5 y), with no apparent plateau.
The lower risk of SMN in survivors of childhood leukemia compared with survivors of childhood solid tumors is due to the less frequent use of radiotherapy in the former group (Löning et al. 2000; Leung et al. 2001; Neglia et al. 2001; Bhatia et al. 2002; Pui et al. 2003; Hijiya et al. 2007; Friedman et al. 2010; Tukenova et al. 2011). The most frequent second neoplasms following radiotherapy for acute lymphoblastic leukemia are brain tumors, acute myeloid leukemia, and carcinomas of skin, thyroid, and parotid gland (Löning et al. 2000; Neglia et al. 2001; Bhatia et al. 2002; Pui et al. 2003; Hijiya et al. 2007). The majority of late-onset radiation-associated second neoplasms in survivors of acute lymphoblastic leukemia are low-grade (i.e., meningiomas and basal cell carcinomas) (Goshen et al. 2007; Hijiya et al. 2007).
The risk of a radiation-associated brain tumor in survivors of childhood cancer is positively associated with young age at time of radiation (<6 y), higher radiation dose (>30 Gy), and concomitant treatment with antimetabolites (especially in patients with thiopurine methyltransferase deficiency) or growth hormone (Walter et al. 1998; Relling et al. 1999; Ergun-Longmire et al. 2006; Neglia et al. 2006). In the Berlin-Frankfurt-Münster trials, which involved multimodal intensive therapy that includes chemotherapy and radiation (Löning et al. 2000; Schrappe et al. 2000), the 15 y cumulative risk of SMNs was 1.7% (95% CI = 0.1–3.4 %) among patients treated with 12 Gy cranial irradiation, which was lower, albeit not statistically significantly, compared with a 15 y cumulative risk of 3.2% (95% CI = 1.1–5.3 %) for those receiving at least 18 Gy. The markedly reduced use of prophylactic cranial irradiation in contemporary clinical trials for pediatric leukemia is anticipated to reduce the occurrence of SMNs. Indeed, the 10 y cumulative risk of SMNs ranged from only 0.1% [standard error (SE) = 0.1%] to 3.3% (SE = 1.2%) in patients treated for leukemia in the 1990s (Pui et al. 2011) and was particularly low (i.e., 0.1 and 0.3%) in the two studies that did not use cranial irradiation (Pui et al. 2009; Kamps et al. 2010).
SMNS WITH RADIATION DOSE-RESPONSE RELATIONSHIPS
Table 1 summarizes epidemiological studies of SMNs following radiotherapy that included the estimated dose of radiation to the organ of interest. Most of these studies had a nested case-control design, and the relative risk parameter served as the primary risk measure.
Radiotherapy is associated with secondary leukemia (Boice et al. 1987; Curtis et al. 1992, 1994), and several studies have reported an attenuation of the risk of secondary leukemia at very high radiation doses. For example, in an international study of nearly 150,000 women treated for cervical cancer, the risk of leukemia increased with increasing dose to active bone marrow up to ~4 Gy (RR ~2.5) and then declined to ~1.5 at a dose of 17 Gy (Boice et al. 1987). In these studies (Boice et al. 1987; Curtis et al. 1992), secondary chronic lymphocytic leukemia was not associated with radiotherapy (Boice et al. 1987; Curtis et al. 1992).
Case-control studies of female breast cancer following treatment for Hodgkin lymphoma before age 30 y (Travis et al. 2003) and in childhood cancer survivors (Inskip et al. 2009) provide evidence of a radiation dose-response relationship. In both studies, the risk of breast cancer increased with increasing radiation dose to the breast, reaching an odds ratio of 8 or more at doses of 40 Gy or more with no evidence of a downturn in the risk of breast cancer at the highest doses (Fig. 1a). A radiation dose to the ovary exceeding 5 Gy reduced the slope of the radiation dose-response relationship for breast cancer in women given chest radiotherapy, and alkylating agents also reduced the risk of breast cancer in Hodgkin lymphoma survivors. Several studies (Travis et al. 2003; van Leeuwen et al. 2003; Basu et al. 2008; De Bruin et al. 2009a) have shown that this latter effect is due to treatment-related premature menopause. Dose-response relationships have been identified at lower doses (mainly doses <5 Gy) for contralateral breast cancer but only among patients diagnosed with a first breast cancer before the age of 45 y (Hooning et al. 2008; Stovall et al. 2008; Boice et al. 1992).
An international study of lung cancer in survivors of Hodgkin lymphoma demonstrated a statistically significant radiation dose-response relationship (Travis et al. 2002; Gilbert et al. 2003). This radiation dose-response was well described by a linear relationship with a modeled risk of sevenfold at 40 Gy; thus, lung cancer risk increased with increasing radiation dose (i.e., a downturn in risk at the highest doses was not apparent). This finding implies that the lower radiation doses administered to treat Hodgkin lymphoma today will likely be associated with lower risks of lung cancer. Elevated risk was apparent 5–9 y after radiation treatment and persisted for at least 20 y. The combined effect of radiation dose and therapy with alkylating agents was additive, whereas the combined effect of radiation and smoking was more than additive (P < 0.001) and consistent with a multiplicative relationship.
There are few data on the relationship between radiation dose incidentally received by active bone marrow in the course of cancer treatment and subsequent leukemia risk. Kaldor et al. (1990) found that among 11 Hodgkin lymphoma survivors who developed leukemia, the risk of leukemia in those who had received >20 Gy to the bone marrow was seven times larger than in those who had received smaller doses.
Information regarding radiation dose-response relationships and subsequent tumors of the central nervous system is sparse. Neglia et al. (2006) found statistically significant radiation dose-response relationships for both gliomas and meningiomas in childhood cancer survivors, and the relative risks at a given dose were higher for meningiomas than for gliomas (Fig. 1b). In a case-control study of childhood cancer survivors (Sigurdson et al. 2005), the risk of thyroid cancer increased with increasing dose to ~29 Gy (RR ~10) and then decreased for doses of 30 Gy or higher (Fig. 1c).
Increased risks of bone cancer and soft tissue sarcomas have been reported in many patient populations that received therapeutic doses exceeding 10 Gy (Tucker et al. 1987; Boice et al. 1988; Wong et al. 1997). Especially, high relative risks of these SMNs have been observed among childhood cancer survivors, and a genetic interaction has been demonstrated in retinoblastoma survivors (Wong et al. 1997). A large international case-control study of cervical cancer that provided dose-response curves for 16 SMNs in addition to leukemia found statistically significant dose-response relationships at very high doses (≥30 Gy) for cancers of the rectum and bladder and all female genital cancers (Boice et al. 1988).
CVD IN PATIENTS WHO RECEIVED RADIATION THERAPY
Radiation, chemotherapy, and biological agents, independently and in combination, increase the risk of CVD in cancer survivors. For survivors of some cancers, radiotherapy-related CVD is the leading noncancer cause of mortality (Applefeld et al. 1981; Kaldor et al. 1990; Ling et al. 1999; Swerdlow et al. 2000; van Leeuwen et al. 2003; Reulen et al. 2010). Radiation-related CVD includes pericardial disease, coronary artery disease, valvular dysfunction, conduction abnormalities, and cerebrovascular disease. However, the risk of pericarditis is rare with modern techniques of irradiation and dose fractionation. When at least 60% of the heart is irradiated at doses of 40 Gy or less, the risk for mild pericarditis is <5%, and severe pericarditis is rare (Stewart et al. 1995).
Coronary artery disease results from injury and replacement of damaged cells by myofibroblasts and the deposition of platelets, followed by a cascade of events that result in atherosclerosis (Mauch et al. 2005). Myocardial infarction is one of the most common types of CVD in long-term Hodgkin lymphoma survivors. High-dose (i.e., >30–35 Gy) mediastinal radiation, particularly in younger Hodgkin lymphoma patients, increases the risk of coronary artery disease (Hancock et al. 1993a; Aleman et al. 2007). The resulting high rate of complications and/or death most frequently occurs in Hodgkin lymphoma patients who have diastolic dysfunction (Heidenreich et al. 2005). Among 2232 consecutive Hodgkin lymphoma patients treated from 1960 through 1991, irradiated children and adolescents had a markedly increased risk of death due to heart disease (RR = 28–37), and all of these deaths were in patients who received doses of 42–45 Gy (Hancock et al. 1993b). When this analysis was extended to include all Hodgkin lymphoma patients, the overall relative risk of death from acute myocardial infarction was 3.2 (Hancock et al. 1993b). The increased risks of death from myocardial infarction were statistically significant within 5 y after radiotherapy, the average time from completion of radiotherapy to myocardial infarction was 10.3 y, and the risk of death from myocardial infarction remained elevated throughout the follow-up period (>20 y).
Many studies of breast cancer survivors have reported a statistically significant increase in coronary artery disease and/or nonfatal myocardial infarction associated with left-sided radiotherapy compared with right-sided radiotherapy or no radiotherapy (Højris et al. 1999; Vallis et al. 2002; Hill-Kayser et al. 2006; Borger et al. 2007; Correa et al. 2007; Hooning et al. 2007; Paszat et al. 2007). Breast cancer patients treated with internal mammary node radiotherapy may also be at increased risk for coronary artery disease (Harris et al. 2006; Correa et al. 2007; Hooning et al. 2008).
Radiotherapy is associated with an increased risk of valvular dysfunction (Carlson et al. 1991; Tamura et al. 2007). Hull et al. (2003) reported that valvular dysfunction developed in 25 of 415 Hodgkin lymphoma survivors at a median of 22 y after radiotherapy. In a large Dutch study of breast cancer survivors (Hooning et al. 2007), the hazard ratio of valvular dysfunction for internal mammary node radiotherapy vs. no radiotherapy was 3.17 (95% CI = 1.90–5.29). The 2009 CCSS survey (Mulrooney et al. 2009) showed that the cumulative incidence of self-reported valvular disease increased with increasing cardiac radiation dose.
Radiation may cause fibrosis of cardiac conduction pathways, which can lead to life-threatening arrhythmias or other conduction defects. Serious post-radiation abnormalities include atrioventricular nodal bradycardia, all levels of heart block including complete heart block, and sick sinus syndrome (Orzan et al. 1993). The frequency of one type of cardiac conduction damage (i.e., QTc > 0.44 s) in 134 childhood cancer survivors was 12.5% after chest radiotherapy alone and 18.9% after radiotherapy and anthracyclines (Orzan et al. 1993). Persistent fixed-rate tachycardia and loss of circadian variability in the heart rate have also been documented following chest radiotherapy that resulted in cardiac exposure. In one study (Adams et al. 2004), 74.5% of long-term survivors of Hodgkin lymphoma treated with chest radiotherapy had a cardiac conduction defect or arrhythmia, 31% had sustained tachycardia, and 57% had a monotonous heart rate. Autonomic nervous system dysfunction could lead to the decreased perception of angina observed by some patients.
Myocardial infarction due to radiotherapy can also lead to congestive heart failure. When myocardial dysfunction develops after standard-dose mediastinal irradiation, it is typically mild or subclinical (Glanzmann et al. 1998) and involves diastolic and systolic left ventricular dysfunction (Cameron et al. 1998). Restrictive cardiomyopathy is more common in cancer survivors treated with radiotherapy who have not received an anthracycline (Tolba and Deliargyris 1999). Subtle left ventricular dysfunction has been detected by echocardiography and radionuclide angiography in Hodgkin lymphoma patients evaluated a few years after mediastinal irradiation (Marks et al. 2005). Two retrospective studies (Harris et al. 2006; Hooning et al. 2007) of congestive heart failure among irradiated breast cancer patients yielded conflicting results. A multi-institutional study with a median follow-up of 18 y found an increased risk of congestive heart failure with radiotherapy compared with no radiotherapy (Hooning et al 2007), whereas another investigation (Harris et al. 2006) found no increased incidence of congestive heart failure associated with radiotherapy laterality or internal mammary node radiotherapy.
Few analytic data describe the relationship between radiation dose to the heart and adverse outcomes. The 2009 CCSS survey is thus noteworthy for the detailed dose-response evaluations conducted following radiotherapy and anthracycline treatments and the risks (albeit self-reported) of congestive heart failure, myocardial infarction, pericardial disease, and valvular abnormalities (Fig. 2). Compared with siblings, childhood cancer survivors were statistically significantly more likely to report congestive heart failure (HR = 5.9, 95% CI = 3.4–9.6), myocardial infarction (HR = 5.0, 95% CI = 2.3–0.4), pericardial disease (HR = 6.3, 95% CI = 3.3–11.9), and valvular abnormalities (HR = 4.8, 95% CI = 3.0–7.6). Cardiac radiation exposure of at least 15 Gy increased the risk of congestive heart failure, myocardial infarction, pericardial disease, and valvular abnormalities by two- to sixfold compared with nonirradiated survivors. There was no evidence for increased risks of any of these conditions following exposure to <5 Gy, and the slight elevations in these risks were not statistically significant at exposures between 5 and 15 Gy. The hazard ratios for the four cardiac conditions ranged from 3.6 to 5.5 for cardiac doses >35 Gy. The cumulative incidence of adverse cardiac outcomes in childhood cancer survivors continued to increase up to 30 y after diagnosis and ranged from ~2% to slightly >4% overall, but to much higher levels for those who received the highest cardiac radiation doses (Fig. 2) and the highest cumulative dose of anthracyclines. Recent data from the German-Austrian DAL-HD (German Association for Childhood Leukemia Research and Treatment and Hodgkin’s disease) studies show a dose-response relationship for cardiac diseases in children treated for Hodgkin lymphoma with combined anthracycline-based chemotherapy (cumulative doxorubicin dose was uniformly 160 mg m−2) and radiation (Schellong et al. 2010). The 25 y cumulative incidence of cardiac disease was 3% with no radiotherapy, 5% after 20 Gy, 6% after 25 Gy, 10% after 30 Gy, and 21% after 36 Gy (Schellong et al. 2010).
Patients treated for head and neck cancer with radiation doses of 40–70 Gy, and particularly with doses >60 Gy, have an elevated risk for stroke and occlusive carotid artery disease (Smith et al. 2008; De Bruin et al. 2009b; Scott et al. 2009). In one study (De Bruin et al. 2009b), the median time from radiotherapy to stroke diagnosis was 10.9 y (range = 1.3–21 y). Another study (Scott et al. 2009) reported 66 cerebrovascular events among 2,567 head and neck cancer patients who were treated with 30–66 Gy radiotherapy compared with only 12 events among 4,119 nonirradiated patients (odds ratio = 9.0; P < 0.001).
In a 2009 study of 2,201 5 y survivors of Hodgkin lymphoma (De Bruin et al. 2009b), 96 patients developed cerebrovascular disease (55 had a stroke, 31 had a transient ischemic attack, and 10 had both) at a median age of 52 y. The standardized incidence ratio was 2.2 for stroke and 3.1 for transient ischemic attack. Radiation to the neck and mediastinum was an independent risk factor for ischemic cerebrovascular disease (HR = 2.5, 95% CI = 1.1–5.6 compared with no radiotherapy).
The incidence of stroke in the CCSS cohort was almost 10-fold higher than in the sibling comparison group (Bowers et al. 2006). Leukemia survivors were six times more likely to suffer a stroke compared with the siblings, and brain tumor survivors were 29 times more likely. Of the brain tumor cohort, 69 (4.9%) of 1,411 patients who had a history of radiotherapy reported a stroke, and the cumulative incidence of stroke at 25 y after radiation therapy was 6.9% (95% CI = 4.5–9.3%). Cancer survivors who were exposed to cranial radiotherapy at a dose of 30 Gy or higher had an increased risk for stroke, with the highest risk among those treated with a dose of 50 Gy or higher (Bowers et al. 2006). Adult survivors of childhood Hodgkin lymphoma who were treated with thoracic radiotherapy (median dose = 40 Gy), which included mediastinal and neck radiotherapy, had a 5.6-fold increased risk of stroke compared with the siblings.
CONCLUSIONS AND RESEARCH RECOMMENDATIONS
The conclusions and recommendations of the NCRP (2011) are summarized in Box 1 and reproduced in their entirety in the Supplemental Digital Content 2 (http://links.lww.com/HP/A18). The reader is referred to NCRP Report No. 170 (NCRP 2011) for in-depth discussion of each of the conclusions and recommendations. In summary, although modern therapies prolong the lives of cancer patients, this success carries an increased risk of late adverse health effects, including SMNs and CVD. Awareness, evaluation, counseling, and amelioration strategies are recommended (NCRP 2011).
Funding: Supported in part by grant CA21765 from the National Institutes of Health, the American Lebanese Syrian Associated Charities (Ching-Hon Pui), and the University of Rochester Medical Center (Lois B. Travis).
Notes: We wish to thank Laura Atwell (NCRP) and Charles Church (National Center for Physical Acoustics, University of Mississippi) for their support of NCRP Scientific Committee 1–17, as well as Tom Tenforde (President, NCRP) and David Schauer (Executive Director, NCRP). We are also indebted to Laura Brumbaugh (URMC) for expert editorial assistance. The NCRP Committee was responsible for preparing the comprehensive report (upon which this paper is based) with NCRP’s financial support from the National Cancer Institute under Grant Number R24 CA074206. The funding agency had no role in design, analysis, or interpretation of the reviewed data; in the decision to submit the paper for publication; or the writing of the paper. The content of this paper is the sole responsibility of the co-authors and does not necessarily reflect the views of the funding agency (NCI). NCRP Report No. 170 (2011) is available at http://www.ncrponline.org.
Before publication, NCRP reports undergo comprehensive review by an outside panel of experts, who provide substantive and critical comments that are then addressed by the scientific committee. The revised report is then reviewed by all members of the NCRP before final revision, publication, and endorsement by the NCRP.
Abdel-Wahab M, Reis IM, Wu J, Duncan R. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: An analysis of SEER data. Urology 74: 866–871; 2009.
Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, Greenbaum N, Mauch P, Lipshultz SE. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 22: 3139–3148; 2004.
Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van’t Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H, van Leeuwen FE. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109: 1878–1886; 2007.
Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK, eds. SEER cancer statistics review, 1975–2007 [online]. 2010. Available at http://seer.cancer.gov/csr/1975_2007
. Accessed 4 October 2010.
Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E, Antoniou AC, Wagner T, Simard J, Evans G, Peock S, Fricker JP, Nogues C, Van’t Veer L, Van Leeuwen FE, Goldgar DE. Effect of chest x-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: A report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ Group. J Clin Oncol 24: 3361–3366; 2006.
Angèle S, Romestaing P, Moullan N, Vuillaume M, Chapot B, Friesen M, Jongmans W, Cox DG, Pisani P, Gérard JP, Hall J. ATM haplotypes and cellular response to DNA damage: Association with breast cancer risk and clinical radiosensitivity. Cancer Res 63 (24): 8717–8725; 2003.
Applefeld MM, Cole JF, Pollock SH, Sutton FJ, Slawson RG, Singleton RT, Wiernik PH. The late appearance of chronic pericardial disease in patients treated by radiotherapy for Hodgkin’s disease. Ann Intern Med 94: 338–341; 1981.
Armstrong GT, Liu W, Leisenring W, Yasui Y, Hammond S, Bhatia S, Neglia JP, Stovall M, Srivastava D, Robison LL. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol 29: 3056–3064; 2011.
Averbeck D. Does scientific evidence support a change from the LNT model for low-dose radiation risk extrapolation? Health Phys 97: 493–504; 2009.
Azria D, Ozsahin M, Kramar A, Peters S, Atencio DP, Crompton NE, Mornex F, Pèlegrin A, Dubois JB, Mirimanoff RO, Rosenstein BS. Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 14: 6284–6288; 2008.
Backlund MG, Trasti SL, Backlund DC, Cressman VL, Godfrey V, Koller BH. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice. Cancer Res 61: 6577–6582; 2001.
Bassal M, Mertens AC, Taylor L, Neglia JP, Greffe BS, Hammond S, Ronckers CM, Friedman DL, Stovall M, Yasui YY, Robison LL, Meadows AT, Kadan-Lottick NS. Risk of selected subsequent carcinomas in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol 24: 476–483; 2006.
Basu SK, Schwartz C, Fisher SG, Hudson MM, Tarbell N, Muhs A, Marcus KJ, Mendenhall N, Mauch P, Kun LE, Constine LS. Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin’s disease. Int J Radiat Oncol Biol Phys 72: 34–40; 2008.
Bernstein JL, Haile RW, Stovall M, Boice JD Jr, Shore RE, Langholz B, Thomas DC, Bernstein L, Lynch CF, Olsen JH, Malone KE, Mellemkjaer L, Borresen-Dale AL, Rosenstein BS, Teraoka SN, Diep AT, Smith SA, Capanu M, Reiner AS, Liang X, Gatti RA, Concannon P. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women’s environmental cancer and radiation epidemiology study. J Natl Cancer Inst 102: 475–483; 2010.
Berrington de Gonzalez A, Berg CD, Visvanathan K, Robson M. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 101: 205–209; 2009.
Best T, Li D, Skol AD, Kirchhoff T, Jackson SA, Yasui Y, Bhatia S, Strong LC, Domchek SM, Nathanson KL, Olopade OI, Huang RS, Mack TM, Conti DV, Offit K, Cozen W, Robison LL, Onel K. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin’s lymphoma. Nat Med 17: 941–943; 2011.
Bhatia S, Robison LL. Cancer survivorship research: opportunities and future needs for expanding the research base. Cancer Epidemiol Biomarkers Prev 17: 1551–1557; 2008.
Bhatia S, Sather HN, Pabustan OB, Trigg ME, Gaynon PS, Robison LL. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 99: 4257–4264; 2002.
Bhatti P, Struewing JP, Alexander BH, Hauptmann M, Bowen L, Mateus-Pereira LH, Pineda MA, Simon SL, Weinstock RM, Rosenstein M, Stovall M, Preston DL, Linet MS, Doody MM, Sigurdson AJ. Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. radiologic technologists. Int J Cancer 122: 177–182; 2008a.
Bhatti P, Doody MM, Alexander BH, Yuenger J, Simon SL, Weinstock RM, Rosenstein M, Stovall M, Abend M, Preston DL, Pharoah P, Struewing JP, Sigurdson AJ. Breast cancer risk polymorphisms and interaction with ionizing radiation among U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev 17: 2007–2011; 2008b.
Bhatti P, Doody MM, Rajaraman P, Alexander BH, Yeager M, Hutchinson A, Burdette L, Thomas G, Hunter DJ, Simon SL, Weinstock RM, Rosenstein M, Stovall M, Preston DL, Linet MS, Hoover RN, Chanock SJ, Sigurdson AJ. Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists. Radiat Res 173: 214–224; 2010.
Boice JD Jr, Blettner M, Kleinerman RA, Stovall M, Moloney WC, Engholm G, Austin DF, Bosch A, Cookfair DL, Krementz ET. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 79: 1295–1311; 1987.
Boice JD Jr, Engholm G, Kleinerman RA, Blettner M, Stovall M, Lisco H, Moloney WC, Austin DF, Bosch A, Cookfair DL, Krementz ET, Latourette HB, Merrill JA, Peters LJ, Schulz MD, Storm HH, Björkholm E, Pettersson F, Coleman MP, Fraser P, Neal FE, Prior P, Choi NW, T. Hislop TG, Koch M, Kreiger N, Robb D, Robson D, Thomson DH, Lochmüller H, von Fournier D, Frischkorn R, Kjørstad KE, Rimpela A, Pejovic M-H, Pompe Kirn V, Stankusova H, Berrino F, Sigurdsson K, Hutchison GB, MacMahon B. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 116: 3–55; 1988.
Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 326: 781–785; 1992.
Borger JH, Hooning MJ, Boersma LJ, Snijders-Keilholz A, Aleman BM, Lintzen E, van Brussel S, van der Toorn PP, Alwhouhayb M, van Leeuwen FE. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: The role of irradiated heart volume. Int J Radiat Oncol Biol Phys 69: 1131–1138; 2007.
Bortfeld T, Schmidt-Ullrich R, De Neve W, Wazer DE, eds. Image-guided IMRT. Berlin, Germany: Springer; 2005.
Bowers DC, Liu Y, Leisenring W, McNeil E, Stovall M, Gurney JG, Robison LL, Packer RJ, Oeffinger KC. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: A report from the Childhood Cancer Survivor Study. J Clin Oncol 24: 5277–5282; 2006.
Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88: 398–406; 2000.
Breslow NE, Lange JM, Friedman DL, Green DM, Hawkins MM, Murphy MF, Neglia JP, Olsen JH, Peterson SM, Stiller CA, Robison LL. Secondary malignant neoplasms after Wilms tumor: an international collaborative study. Int J Cancer 127: 657–666; 2010.
Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 23: 2208–2214; 2005.
Burns FJ, Tang M, Frenkel K, Nadas A, Wu F, Uddin A, Zhang R. Induction and prevention of carcinogenesis in rat skin exposed to space radiation. Radiat Environ Biophys 46: 195–199; 2007.
Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, Fan G, Stone NN, Ostrer H, Rosenstein BS. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 170: 49–59; 2008.
Cameron EH, Lipshultz SE, Tarbell NJ, Mauch PM. Cardiovascular disease in long-term survivors of pediatric Hodgkin’s disease. Prog Pediatr Cardiol 8: 139–144; 1998.
Carlson RG, Mayfield WR, Normann S, Alexander JA. Radiation-associated valvular disease. Chest 99: 538–545; 1991.
Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, Stovall M, Robison LL, Hudson MM. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study. Blood 117: 1806–1816; 2011.
Chang-Claude J, Popanda O, Tan XL, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Ambrosone CB. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 11: 4802–4809; 2005.
Chang-Claude J, Ambrosone CB, Lilla C, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Popanda O. Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer 100: 1680–1686; 2009.
Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG, Shannon KM. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell 8: 337–348; 2005.
Chaturvedi AK, Engels EA, Gilbert ES. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 99: 1634–1643; 2007.
Chrouser K, Leibovich B, Bergstralh E, Zincke H, Blute M. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 174: 107–110; 2005.
Chung P, Mayhew LA, Warde P, Winquist E, Lukka H. Management of stage I seminomatous testicular cancer: A systematic review. Clin Oncol (R Coll Radiol) 22: 6–16; 2010.
Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 11: 415–425; 2010.
Correa CR, Litt HI, Hwang WT, Ferrari VA, Solin LJ, Harris EE. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 25: 3031–3037; 2007.
Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326: 1745–1751; 1992.
Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Holowaty E, Karjalainen S, Langmark F, Nasca PC, Schwartz AG, Schymura MJ, Storm HH, Toogood P, Weyer P, Moloney WC. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst 86: 1315–1324; 1994.
De Bruin ML, Sparidans J, van’t Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Russell NS, Broeks A, Baaijens MH, Aleman BM, van Leeuwen FE. Breast cancer risk in female survivors of Hodgkin’s lymphoma: Lower risk after smaller radiation volumes. J Clin Oncol 27: 4239–4246; 2009a.
De Bruin ML, Dorresteijn LD, van’t Veer MB, Krol AD, van der Pal HJ, Kappelle AC, Boogerd W, Aleman BM, van Leeuwen FE. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 101: 928–937; 2009b.
Delaney TF, Kooy HM. Proton and charged particle radiotherapy. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2008.
De Ruyck K, Van Eijkeren M, Claes K, Bacher K, Vral A, De Neve W, Thierens H. TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat Oncol Biol Phys 65: 1240–1248; 2006.
Deutsch M, Land SR, Begovic M, Wieand HS, Wolmark N, Fisher B. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer 98: 1362–1368; 2003.
Dores GM, Cote TR, Travis LB. New malignancies following Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma. In: New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; NIH Pub No. 05-5302; 2006.
Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 91: 3494–3498; 2006.
Friedman DL, Rovo A, Leisenring W, Locasciulli A, Flowers ME, Tichelli A, Sanders JE, Deeg HJ, Socie G. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: A report from the FHCRC and the EBMT-Late Effect Working Party. Blood 111: 939–944; 2008.
Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, Donaldson SS, Meadows AT, Robison LL, Neglia JP. Subsequent neoplasms in 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 102: 1083–1095; 2010.
Fry RJM, Ley RR. Ultraviolet radiation carcinogenesis. In: Slaga TJ, ed. Mechanisms of tumor promotion. Boca Raton, FL: CRC Press; 1984: 73–96.
Gilbert ES, Stovall M, Gospodarowicz M, Van Leeuwen FE, Andersson M, Glimelius B, Joensuu T, Lynch CF, Curtis RE, Holowaty E, Storm H, Pukkala E, van’t Veer MB, Fraumeni JF, Boice JD Jr, Clarke EA, Travis LB. Lung cancer after treatment for Hodgkin’s disease: Focus on radiation effects. Radiat Res 159: 161–173; 2003.
Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 46: 51–62; 1998.
Goshen Y, Stark B, Kornreich L, Michowiz S, Feinmesser M, Yaniv I. High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 49: 294–297; 2007.
Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27: 5887–5892; 2009.
Greene MH, Young RC, Merrill JM, DeVita VT. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin’s lymphoma. Cancer Res 43: 1891–1898; 1983.
Gutiérrez-Enríquez S, Fernet M, Dörk T, Bremer M, Lauge A, Stoppa-Lyonnet D, Moullan N, Angèle S, Hall J. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer 40: 109–119; 2004.
Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 65: 1–7; 2006.
Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 11: 1208–1215; 1993a.
Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 270: 1949–1955; 1993b.
Harris EE, Correa C, Hwang WT, Liao J, Litt HI, Ferrari VA, Solin LJ. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 24: 4100–4106; 2006.
Heidenreich PA, Hancock SL, Vagelos RH, Lee BK, Schnittger I. Diastolic dysfunction after mediastinal irradiation. Am Heart J 150: 977–982; 2005.
Hemminki K, Ji J, Forsti A. Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res 67: 868–870; 2007.
Henderson TO, Whitton J, Stovall M, Mertens AC, Mitby P, Friedman D, Strong LC, Hammond S, Neglia JP, Meadows AT, Robison L, Diller L. Secondary sarcomas in childhood cancer survivors: A report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 99: 300–308; 2007.
Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, Razzouk BI, Ribeiro RC, Rubnitz JE, Sandlund JT, Rivera GK, Evans WE, Relling MV, Pui CH. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 297: 1207–1215; 2007.
Hill-Kayser CE, Harris EE, Hwang WT, Solin LJ. Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation. Int J Radiat Oncol Biol Phys 66: 1313–1319; 2006.
Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 106: 9362–9367; 2009.
Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M, Tsichlis PN, Shirley Liu X, Struhl K. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 17: 348–361; 2010.
Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, Hall P, Langmark F, Pukkala E, Andersson M, Kaijser M, Joensuu H, Fosså SD, Travis LB. Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J Clin Oncol 25: 1489–1497; 2007.
Højris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 354: 1425–1430; 1999.
Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, Taylor CW, van Leeuwen FE. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99: 365–375; 2007.
Hooning MJ, Aleman BM, Hauptmann M, Baaijens MH, Klijn JG, Noyon R, Stovall M, van Leeuwen FE. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol 26: 5561–5568; 2008.
Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Körbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. Ann Oncol 13: 450–459; 2002.
Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290: 2831–2837; 2003.
IMRTCWG. Intensity-modulated radiotherapy: Current status and issues of interest. Intensity Modulated Radiation Therapy Collaborative Working Group. Int J Radiat Oncol Biol Phys 51: 880–914; 2001.
Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28: 4674–4682; 2010.
Inskip PD, Robison LL, Stovall M, Smith SA, Hammond S, Mertens AC, Whitton JA, Diller L, Kenney L, Donaldson SS, Meadows AT, Neglia JP. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 27: 3901–3907; 2009.
Kaldor JM, Day NE, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, Bell J, Pedersen D, Band P, Assouline D, Koch M, Choi W, Prior P, Blair V, Langmark F, Pompe Kirn V, Neal F, Peters D, Pfeiffer R, Karjalainen S, Cuzick J, Sutcliffe SB, Somers R, Pellae-Cosset B, Pappagallo GL, Fraser P, Storm H, Stovall M. Leukemia following Hodgkin’s disease. N Engl J Med 322: 7–13; 1990.
Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, Bierings M, Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 24: 309–319; 2010.
Kaufman EL, Jacobson JS, Hershman DL, Desai M, Neugut AI. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 26: 392–398; 2008.
Kendal WS, Eapen L, Macrae R. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer. Int J Radiat Oncol Biol Phys 65: 661–668; 2006.
Kennedy AR. Factors that modify radiation-induced carcinogenesis. Health Phys 97: 433–445; 2009.
Kennedy AR, Davis JG, Carlton W, Ware JH. Effects of dietary antioxidant supplementation on the development of malignant lymphoma and other neoplastic lesions in mice exposed to proton or iron-ion radiation. Radiat Res 169: 615–625; 2008.
Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet A. Radiation-induced sarcomas after radiotherapy for breast carcinoma: A large-scale single-institution review. Cancer 104: 856–863; 2005.
Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A. Risk of second malignancies after adjuvant radiotherapy for breast cancer: A large-scale, single-institution review. Int J Radiat Oncol Biol Phys 68: 359–363; 2007.
Kleinerman RA, Curtis RE, Boice JD Jr, Flannery JT, Fraumeni JF Jr. Second cancers following radiotherapy for cervical cancer. J Natl Cancer Inst 69: 1027–1033; 1982.
Kleinerman RA, Boice JD Jr, Storm HH, Sparen P, Andersen A, Pukkala E, Lynch CF, Hankey BF, Flannery JT. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer 76: 442–452; 1995.
Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, Li FP, Fraumeni JF Jr. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: An extended follow-up. J Clin Oncol 23: 2272–2279; 2005.
Knight JA, Skol AD, Shinde A, Hastings D, Walgren RA, Shao J, Tennant TR, Banerjee M, Allan JM, Le Beau MM, Larson RA, Graubert TA, Cox NJ, Onel K. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 113: 5575–5582; 2009.
Kuptsova N, Chang-Claude J, Kropp S, Helmbold I, Schmezer P, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Onel K, Ambrosone CB. Genetic predictors of long-term toxicities after radiation therapy for breast cancer. Int J Cancer 122: 1333–1339; 2008.
Landgren O, Pfeiffer RM, Stewart L, Gridley G, Mellemkjaer L, Hemminki K, Goldin LR, Travis LB. Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. Int J Cancer 120: 1099–1102; 2007.
Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 102: 316–319; 1951.
Leksell L. Cerebral radiosurgery. I. Gammathalanotomy in two cases of intractable pain. Acta Chir Scand 134: 585–595; 1968.
Leung W, Ribeiro RC, Hudson M, Tong X, Srivastava DK, Rubnitz JE, Sandlund JT, Razzouk BI, Evans WE, Pui CH. Second malignancy after treatment of childhood acute myeloid leukemia. Leukemia 15: 41–45; 2001.
Li X, Dumont P, Della Pietra A, Shetler C, Murphy ME. The codon 47 polymorphism in p53 is functionally significant. J Biol Chem 280: 24245–24251; 2005.
Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 96: 238–242; 2001.
Ling LH, Oh JK, Schaff HV, Danielson GK, Mahoney DW, Seward JB, Tajik AJ. Constrictive pericarditis in the modern era: Evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation 100: 1380–1386; 1999.
Little JB. Radiation carcinogenesis. Carcinogenesis 21: 397–404; 2000.
Little MP, de Vathaire F, Shamsaldin A, Oberlin O, Campbell S, Grimaud E, Chavaudra J, Haylock RG, Muirhead CR. Risks of brain tumour following treatment for cancer in childhood: Modification by genetic factors, radiotherapy and chemotherapy. Int J Cancer 78: 269–275; 1998.
Longo DL. Radiation therapy in Hodgkin disease: Why risk a Pyrrhic victory? J Natl Cancer Inst 97: 1394–1395; 2005.
Löning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm H, Schrappe M. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 95: 2770–2775; 2000.
Lönn S, Bhatti P, Alexander BH, Pineda MA, Doody MM, Struewing JP, Sigurdson AJ. Papillary thyroid cancer and polymorphic variants in TSHR- and RET-related genes: A nested case-control study within a cohort of U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev 16: 174–177; 2007.
Lutz W, Winston KR, Maleki N. A system for stereotactic radiosurgery with a linear accelerator. Int J Radiat Oncol Biol Phys 14: 373–381; 1988.
Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M, Hollis D, Lind P, Tisch A, Wong TZ, Borges-Neto S. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 63: 214–223; 2005.
Mauch P, Ng A, Aleman B, Carde P, Constine L, Diehl V, Dinshaw K, Gospodarowicz M, Hancock S, Hodgson D, Hoppe R, Liang R, Loeffler M, Specht L, Travis LB, Wirth A, Yahalom J. Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin’s disease: July 9–16, 2003, Bellagio, Italy. Eur J Haematol Suppl 66: 68–76; 2005.
Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S, Fay JW, Freytes CO, Goldstein SC, Herzig RH, Keating A, Miller CB, Nevill TJ, Pecora AL, Rizzo JD, Williams SF, Li CY, Travis LB, Weisdorf DJ. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: A multicenter case-control study. Blood 101: 2015–2023; 2003.
Moon K, Stukenborg GJ, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer. Cancer 107: 991–998; 2006.
Movsas B, Hanlon AL, Pinover W, Hanks GE. Is there an increased risk of second primaries following prostate irradiation? Int J Radiat Oncol Biol Phys 41: 251–255; 1998.
Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, Hoskin PJ, Linch DC. Risk of second malignancy after non-Hodgkin’s lymphoma: A British Cohort Study. J Clin Oncol 24: 1568–1574; 2006.
Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339: b4606; 2009.
Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim-Sing C, Isaacs C, Domchek S, Sun P. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet Oncol 7: 402–406; 2006.
NCRP. Second primary cancers and cardiovascular disease after radiotherapy. Bethesda, MD: National Council on Radiation Protection and Measurements; NCRP Report No. 170; 2011.
Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, Donaldson SS, Meadows AT, Robison LL. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 93: 618–629; 2001.
Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, Yasui Y, Kasper CE, Mertens AC, Donaldson SS, Meadows AT, Inskip PD. New primary neoplasms of the central nervous system in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 98: 1528–1537; 2006.
Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 20: 2101–2108; 2002a.
Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100: 1989–1996; 2002b.
NHGRI, A catalog of published genome-wide association studies [online]. 2010. Avalable at www.genome.gov/26525384
. Accessed 29 March 2010.
Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber DA, Diller L. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin’s disease. J Clin Oncol 17: 1259; 1999.
Nutting C, Camplejohn RS, Gilchrist R, Tait D, Blake P, Knee G, Yao WQ, Ross G, Fisher C, Eeles R. A patient with 17 primary tumours and a germ line mutation in TP53: Tumour induction by adjuvant therapy? Clin Oncol (R Coll Radiol) 12: 300–304; 2000.
O’Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin’s lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 28: 1232–1239; 2010.
Offit K, Gilad S, Paglin S, Kolachana P, Roisman LC, Nafa K, Yeugelewitz V, Gonzales M, Robson M, McDermott D, Pierce HH, Kauff ND, Einat P, Jhanwar S, Satagopan JM, Oddoux C, Ellis N, Skaliter R, Yahalom J. Rare variants of ATM and risk for Hodgkin’s disease and radiation-associated breast cancers. Clin Cancer Res 8: 3813–3819; 2002.
Orzan F, Brusca A, Gaita F, Giustetto C, Figliomeni MC, Libero L. Associated cardiac lesions in patients with radiation-induced complete heart block. Int J Cardiol 39: 151–156; 1993.
Paszat LF, Vallis KA, Benk VM, Groome PA, Mackillop WJ, Wielgosz A. A population-based case-cohort study of the risk of myocardial infarction following radiation therapy for breast cancer. Radiother Onco 82: 294–300; 2007.
Pazzaglia S, Mancuso M, Tanori M, Atkinson MJ, Merola P, Rebessi S, Di Majo V, Covelli V, Hahn H, Saran A. Modulation of patched-associated susceptibility to radiation induced tumorigenesis by genetic background. Cancer Res 64: 3798–3806; 2004.
Pazzaglia S, Tanori M, Mancuso M, Rebessi S, Leonardi S, Di Majo V, Covelli V, Atkinson MJ, Hahn H, Saran A. Linking DNA damage to medulloblastoma tumorigenesis in patched heterozygous knockout mice. Oncogene 25: 1165–1173; 2006.
Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 95: 3273–3279; 2000.
Pickles T, Phillips N. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984–2000. Radiother Oncol 65: 145–151; 2002.
Pugh TJ, Keyes M, Barclay L, Delaney A, Krzywinski M, Thomas D, Novik K, Yang C, Agranovich A, McKenzie M, Morris WJ, Olive PL, Marra MA, Moore RA. Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients. Clin Cancer Res 15: 5008–5016; 2009.
Pui CH, Cheng C, Leung W, Rai SN, Rivera GK, Sandlund JT, Ribeiro RC, Relling MV, Kun LE, Evans WE, Hudson MM. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 349: 640–649; 2003.
Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360: 2730–2741; 2009.
Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification and therapy of pediatric acute leukemias: An update. J Clin Oncol 29: 551–565; 2011.
Purdy JA. From new frontiers to new standards of practice: advances in radiotherapy planning and delivery. In: Meyer JL, ed. IMRT, IGRT, SBRT—Advances in the treatment planning and delivery of radiotherapy. Basel, Switzerland: Karger; 2007: 18–39.
Purdy JA. Dose to normal tissues outside the radiation therapy patient’s treated volume: A review of different radiation therapy techniques. Health Phys 95: 666–676; 2008.
Rajaraman P, Bhatti P, Doody MM, Simon SL, Weinstock RM, Linet MS, Rosenstein M, Stovall M, Alexander BH, Preston DL, Sigurdson AJ. Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists. Int J Cancer 123: 2713–2716; 2008.
Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE, Walter AW, Evans WE, Pui CH. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354: 34–39; 1999.
Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, Skinner R, Stevens MC, Hawkins MM. Long-term cause-specific mortality among survivors of childhood cancer. JAMA 304: 172–179; 2010.
Ringborg U, Bergqvist D, Brorsson B, Cavallin-Ståhl E, Ceberg J, Einhorn N, Frödin JE, Järhult J, Lamnevik G, Lindholm C, Littbrand B, Norlund A, Nylén U, Rosén M, Svensson H, Möller TR. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001-summary and conclusions. Acta Oncol 42: 357–365; 2003.
Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O, Travis LB, Travis WD, Flowers ME, Friedman DL, Horowitz MM, Wingard JR, Deeg HJ. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113: 1175–1183; 2009.
Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, Green DM, Hammond S, Meadows AT, Mertens AC, Mulvihill JJ, Nathan PC, Neglia JP, Packer RJ, Rajaraman P, Sklar CA, Stovall M, Strong LC, Yasui Y, Zeltzer LK. The Childhood Cancer Survivor Study: A National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 27: 2308–2318; 2009.
Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S, Lombardo M, Buda G, Lazzaro A, Gobbi PG, Stelitano C, Morabito F, Quarta G, Brugiatelli M. Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: A 16-year follow-up study. Haematologica 93: 398–404; 2008.
Schellong G, Riepenhausen M, Bruch C, Kotthoff S, Vogt J, Bölling T, Dieckmann K, Pötter R, Heinecke A, Brämswig J, Dörffel W. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 55: 1145–1152; 2010.
Schonfeld SJ, Bhatti P, Brown EE, Linet MS, Simon SL, Weinstock RM, Hutchinson AA, Stovall M, Preston DL, Alexander BH, Doody MM, Sigurdson AJ. Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists. Cancer Causes Control 21: 1857–1866; 2010.
Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 95: 3310–3322; 2000.
Scott AS, Parr LA, Johnstone PA. Risk of cerebrovascular events after neck and supraclavicular radiotherapy: A systematic review. Radiother Oncol 90: 163–165; 2009.
Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, Evans DG. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: Substantial risks after radiotherapy. J Clin Oncol 24: 2570–2575; 2006.
Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): A nested case-control study. Lancet 365: 2014–2023; 2005.
Sigurdson AJ, Bhatti P, Doody MM, Hauptmann M, Bowen L, Simon SL, Weinstock RM, Linet MS, Rosenstein M, Stovall M, Alexander BH, Preston DL, Struewing JP, Rajaraman P. Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev 16: 2000–2007; 2007.
Sigurdson AJ, Bhatti P, Chang SC, Rajaraman P, Doody MM, Bowen L, Simon SL, Weinstock RM, Linet MS, Rosenstein M, Stovall M, Alexander BH, Preston DL, Struewing JP. Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists. Breast Cancer Res Treat 118: 177–184; 2009a.
Sigurdson AJ, Land CE, Bhatti P, Pineda M, Brenner A, Carr Z, Gusev BI, Zhumadilov Z, Simon SL, Bouville A, Rutter JL, Ron E, Struewing JP. Thyroid nodules, polymorphic variants in DNA repair and RET-related genes, and interaction with ionizing radiation exposure from nuclear tests in Kazakhstan. Radiat Res 171: 77–88; 2009b.
Smith GL, Smith BD, Buchholz TA, Giordano SH, Garden AS, Woodward WA, Krumholz HM, Weber RS, Ang KK, Rosenthal DI. Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol 26: 5119–5125; 2008.
Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 31: 1205–1211; 1995.
Stovall M, Smith SA, Langholz BM, Boice JD Jr, Shore RE, Andersson M, Buchholz TA, Capanu M, Bernstein L, Lynch CF, Malone KE, Anton-Culver H, Haile RW, Rosenstein BS, Reiner AS, Thomas DC, Bernstein JL. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys 72: 1021–1030; 2008.
Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18: 498–509; 2000.
Swerdlow AJ, Schoemaker MJ, Allerton R, Horwich A, Barber JA, Cunningham D, Lister TA, Rohatiner AZ, Vaughan Hudson G, Williams MV, Linch DC. Lung cancer after Hodgkin’s disease: A nested case-control study of the relation to treatment. J Clin Oncol 19: 1610–1618; 2001.
Talwalkar SS, Yin CC, Naeem RC, Hicks MJ, Strong LC, Abruzzo LV. Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. Arch Pathol Lab Med 134: 1010–1015; 2010.
Tamura A, Takahara Y, Mogi K, Katsumata M. Radiation-induced valvular disease is the logical consequence of irradiation. Gen Thorac Cardiovasc Surg 55: 53–56; 2007.
Tan XL, Popanda O, Ambrosone CB, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Chang-Claude J. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat 97: 255–262; 2006.
Teta MJ, Lau E, Sceurman BK, Wagner ME. Therapeutic radiation for lymphoma: Risk of malignant mesothelioma. Cancer 109: 1432–1438; 2007.
Tolba KA, Deliargyris EN. Cardiotoxicity of cancer therapy. Cancer Invest 17: 408–422; 1999.
Travis LB, Curtis RE, Boice JD Jr, Hankey BF, Fraumeni JF Jr. Second cancers following non-Hodgkin’s lymphoma. Cancer 67: 2002–2009; 1991.
Travis LB, Gonzalez CL, Hankey BF, Jaffe ES. Hodgkin’s disease following non-Hodgkin’s lymphoma. Cancer 69: 2337–2342; 1992.
Travis LB, Curtis RE, Glimelius B, Holowaty E, Van Leeuwen FE, Lynch CF, Adami J, Gospodarowicz M, Wacholder S, Inskip P, Tucker MA, Fraumeni JF Jr, Boice JD Jr. Second cancers among long-term survivors of non-Hodgkin’s lymphoma. J Natl Cancer Inst 85: 1932–1937; 1993a.
Travis LB, Holowaty E, Hunter V, Banerjee D, Jones TG, Li CY. Acute basophilic leukemia and acute eosinophilic leukemia after therapy for non-Hodgkin’s lymphoma. Am J Clin Pathol 100: 186; 1993b.
Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, Lynch CF, Hagenbeek A, Li CY, Banks PM, Gospodarowicz MK, Adami J, Wacholder S, Inskip PD, Tucker MA, Boice JD Jr. Risk of leukemia following treatment for non-Hodgkin’s lymphoma. J Natl Cancer Inst 86: 1450–1457; 1994.
Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J, Gospodarowicz MK, Wacholder S, Inskip PD, Tucker MA, Boice JD Jr. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J Natl Cancer Inst 87: 524–530; 1995.
Travis LB, Weeks J, Curtis RE, Chaffey JT, Stovall M, Banks PM, Boice JD Jr. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin’s lymphoma. J Clin Oncol 14: 565–571; 1996.
Travis LB, Andersson M, Gospodarowicz M, van Leeuwen FE, Bergfeldt K, Lynch CF, Curtis RE, Kohler BA, Wiklund T, Storm H, Holowaty E, Hall P, Pukkala E, Sleijfer DT, Clarke EA, Boice JD Jr, Stovall M, Gilbert E. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92: 1165–1171; 2000.
Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr, Boice JD Jr, Gilbert E. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 94: 182–192; 2002.
Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van’t Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD Jr, Gilbert E. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290: 465–475; 2003.
Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, Van’t Veer MB, Joensuu T, Storm H, Stovall M, Boice JD Jr, Gilbert E, Gail MH. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97: 1428–1437; 2005a.
Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD Jr, Dores GM, Gilbert ES. Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 97: 1354–1365; 2005b.
Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele A, Figg WD, Gospodarowicz MK, Hall EJ, Hisada M, Inskip P, Kleinerman R, Little JB, Malkin D, Ng AK, Offit K, Pui CH, Robison LL, Rothman N, Shields PG, Strong L, Taniguchi T, Tucker MA, Greene MH. Cancer survivorship—genetic susceptibility and second primary cancers: Research strategies and recommendations. J Natl Cancer Inst 98: 15–25; 2006.
Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fossa SD. Testicular cancer survivorship: Research strategies and recommendations. J Natl Cancer Inst 102: 1114–1130; 2010.
Travis LB, Bhatia S, Allan JM. Management of adverse effects of treatment: second primary cancers. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: principles and practice of oncology: primer of the molecular biology of cancer. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2011: 2393–2410.
Tucker MA, D’Angio GJ, Boice JD Jr, Strong LC, Li FP, Stovall M, Stone BJ, Green DM, Lombardi F, Newton W. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 317: 588–593; 1987.
Tukenova M, Guibout C, Hawkins M, Quiniou E, Mousannif A, Pacquement H, Winter D, Bridier A, Lefkopoulos D, Oberlin O, Diallo I, de Vathaire F. Radiation therapy and late mortality from second sarcoma, carcinoma, and hematological malignancies after a solid cancer in childhood. Int J Radiat Oncol Biol Phys 80: 339–346; 2011.
Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107: 108–115; 2006.
UNSCEAR. Non-targeted and delayed effects of exposure to ionizing radiation. New York: United Nations Publications; Annex C; 2009.
Vallis KA, Pintilie M, Chong N, Holowaty E, Douglas PS, Kirkbride P, Wielgosz A. Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol 20: 1036–1042; 2002.
van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van Leeuwen FE. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25: 4370–4378; 2007.
van den Belt-Dusebout AW, Aleman BM, Besseling G, de Bruin ML, Hauptmann M, van’t Veer MB, de Wit R, Ribot JG, Noordijk EM, Kerst JM, Gietema JA, van Leeuwen FE. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 75: 1420–1429; 2009.
van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, Boice JD Jr, Burgers JM, Somers R. Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst 87: 1530–1537; 1995.
van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van’t Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 95: 971–980; 2003.
Wallin JL, Tanna N, Misra S, Puri PK, Sadeghi N. Sinonasal carcinoma after irradiation for medulloblastoma in nevoid basal cell carcinoma syndrome. Am J Otolaryngol 28: 360–362; 2007.
Walter AW, Hancock ML, Pui CH, Hudson MM, Ochs JS, Rivera GK, Pratt CB, Boyett JM, Kun LE. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children’s Research Hospital. J Clin Oncol 16: 3761–3767; 1998.
Werbrouck J, De Ruyck K, Duprez F, Veldeman L, Claes K, Van Eijkeren M, Boterberg T, Willems P, Vral A, De Neve W, Thierens H. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: Influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys 73: 1187–1195; 2009.
West C, Rosenstein BS, Alsner J. Establishment of a radiogenomics consortium. Int J Radiat Oncol Biol Phys 76: 1295–1296; 2010.
Wethal T, Haugnes HS, Kjekshus J, Småstuen MC, Ueland T, Aukrust P, Fosså SD. C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors? Eur J Cancer 46: 3425–3433; 2010.
Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, Goldman MB, Seddon JM, Tarbell N, Fraumeni JF Jr, Li FP. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278: 1262–1267; 1997.
Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, Yang H, Khuri FR, Kim E, Gu J, Lotan R, Hong WK. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: Large-scale evaluation of genetic variants. Cancer Prev Res (Phila) 2: 617–624; 2009.
Yahalom J, Portlock CS. Long-term cardiac and pulmonary complications of cancer therapy. Hematol Oncol Clin North Am 22: 305–318; 2008.
Yoshida K, Nakachi K, Imai K, Cologne JB, Niwa Y, Kusunoki Y, Hayashi T. Lung cancer susceptibility among atomic bomb survivors in relation to CA repeat number polymorphism of epidermal growth factor receptor gene and radiation dose. Carcinogenesis 30: 2037–2041; 2009.
Zablotska LB, Neugut AI. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 97: 1404–1411; 2003.
Zablotska LB, Chak A, Das A, Neugut AI. Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am J Epidemiol 161: 330–337; 2005.
Zhang L, Yang M, Bi N, Fang M, Sun T, Ji W, Tan W, Zhao L, Yu D, Lin D, Wang L. ATM polymorphisms are associated with risk of radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 77: 1360–1368; 2010.
Zheng YL, Kosti O, Loffredo CA, Bowman E, Mechanic L, Perlmutter D, Jones R, Shields PG, Harris CC. Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: genotype and phenotype analyses from a case-control study. Int J Cancer 126: 2199–2210; 2010.
Zhu F, Dolle ME, Berton TR. Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res 70: 5851–5859; 2010.
cancer; health effects; medical radiation; National Council on Radiation Protection and Measurements
Supplemental Digital Content
© 2014 by the Health Physics Society
Highlight selected keywords in the article text.